BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24912774)

  • 1. The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.
    Sequeira G; Vanzulli SI; Rojas P; Lamb C; Colombo L; May M; Molinolo A; Lanari C
    Oncotarget; 2014 May; 5(10):3246-60. PubMed ID: 24912774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
    Wargon V; Riggio M; Giulianelli S; Sequeira GR; Rojas P; May M; Polo ML; Gorostiaga MA; Jacobsen B; Molinolo A; Novaro V; Lanari C
    Int J Cancer; 2015 Jun; 136(11):2680-92. PubMed ID: 25363551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
    Rojas PA; May M; Sequeira GR; Elia A; Alvarez M; Martínez P; Gonzalez P; Hewitt S; He X; Perou CM; Molinolo A; Gibbons L; Abba MC; Gass H; Lanari C
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial.
    Elía A; Saldain L; Vanzulli SI; Helguero LA; Lamb CA; Fabris V; Pataccini G; Martínez-Vazquez P; Burruchaga J; Caillet-Bois I; Spengler E; Acosta Haab G; Liguori M; Castets A; Lovisi S; Abascal MF; Novaro V; Sánchez J; Muñoz J; Belizán JM; Abba MC; Gass H; Rojas P; Lanari C
    Clin Cancer Res; 2023 Mar; 29(5):866-877. PubMed ID: 36269797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
    Abascal MF; Elia A; Alvarez M; Pataccini G; Sequeira G; Riggio M; Figueroa V; Lamb CA; Rojas PA; Spengler E; Martínez-Vazquez P; Burruchaga J; Liguori M; Sahores A; Wargon V; Molinolo A; Hewitt S; Lombes M; Sartorius C; Vanzulli SI; Giulianelli S; Lanari C
    Int J Cancer; 2022 May; 150(9):1481-1496. PubMed ID: 34935137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas.
    Wargon V; Fernandez SV; Goin M; Giulianelli S; Russo J; Lanari C
    Breast Cancer Res Treat; 2011 Apr; 126(2):319-32. PubMed ID: 20440553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line.
    Khan JA; Bellance C; Guiochon-Mantel A; Lombès M; Loosfelt H
    PLoS One; 2012; 7(9):e45993. PubMed ID: 23029355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization.
    Khan JA; Amazit L; Bellance C; Guiochon-Mantel A; Lombès M; Loosfelt H
    Mol Endocrinol; 2011 Oct; 25(10):1710-24. PubMed ID: 21816898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
    Wu J; Richer J; Horwitz KB; Hyder SM
    Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid profile in patients with breast cancer and in mice treated with mifepristone.
    Elía A; Saldain L; Lovisi S; Martínez Vazquez P; Burruchaga J; Lamb CA; Lüthy IA; Diez F; Homer NZM; Andrew R; Rojas P; Lanari C
    Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 37962553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential quantitative proteomics reveals key proteins related to phenotypic changes of breast cancer cells expressing progesterone receptor A.
    Pateetin P; Pisitkun T; McGowan E; Boonyaratanakornkit V
    J Steroid Biochem Mol Biol; 2020 Apr; 198():105560. PubMed ID: 31809870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.
    Sahores A; Figueroa V; May M; Liguori M; Rubstein A; Fuentes C; Jacobsen BM; Elía A; Rojas P; Sequeira GR; Álvarez MM; González P; Gass H; Hewitt S; Molinolo A; Lanari C; Lamb CA
    Horm Cancer; 2018 Oct; 9(5):338-348. PubMed ID: 29956066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in Progesterone Receptor Isoform Balance in Normal and Neoplastic Breast Cells Modulates the Stem Cell Population.
    Recouvreux MS; Diaz Bessone MI; Taruselli A; Todaro L; Lago Huvelle MA; Sampayo RG; Bissell MJ; Simian M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32932770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity.
    Sequeira GR; Sahores A; Dalotto-Moreno T; Perrotta RM; Pataccini G; Vanzulli SI; Polo ML; Radisky DC; Sartorius CA; Novaro V; Lamb CA; Rabinovich GA; Salatino M; Lanari C
    Cancer Res; 2021 Mar; 81(5):1375-1387. PubMed ID: 33268529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas.
    Wargon V; Helguero LA; Bolado J; Rojas P; Novaro V; Molinolo A; Lanari C
    Breast Cancer Res Treat; 2009 Aug; 116(3):449-60. PubMed ID: 18677559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.
    Mote PA; Gompel A; Howe C; Hilton HN; Sestak I; Cuzick J; Dowsett M; Hugol D; Forgez P; Byth K; Graham JD; Clarke CL
    Breast Cancer Res Treat; 2015 Jun; 151(2):309-18. PubMed ID: 25917868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
    Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
    Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis.
    Mote PA; Bartow S; Tran N; Clarke CL
    Breast Cancer Res Treat; 2002 Mar; 72(2):163-72. PubMed ID: 12038707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
    Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
    Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoform specificity of progesterone receptor antibodies.
    Fabris V; Abascal MF; Giulianelli S; May M; Sequeira GR; Jacobsen B; Lombès M; Han J; Tran L; Molinolo A; Lanari C
    J Pathol Clin Res; 2017 Oct; 3(4):227-233. PubMed ID: 29085663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.